- AbbVie maintains a 54-year dividend growth streak with a 6.92 dollar annualized payout.
- Strong free cash flow and diversified growth support ABBV dividends in the post-Humira era.
- Next ex-dividend date set for 15 April 2026 with a forward yield near 3.1%.
A Dividend King With Renewed Momentum
AbbVie continues to reinforce its position as one of healthcare’s most reliable income generators. The company has raised its dividend for 54 consecutive years, underscoring a steady track record backed by resilient revenue trends.
Analysts highlight AbbVie’s skilled management of the Humira patent expiration, with immunology leaders Skyrizi and Rinvoq now driving the company’s next phase of expansion. This ongoing strength is reflected in commentary surrounding its Dividend King status.
Investors recently saw the quarterly dividend rise to 1.73 dollars per share from 1.64, resulting in a 6.92 dollar annualized payout and a forward yield near 3.1%.
Strong Cash Flow Supports Long-Term ABBV Dividends
AbbVie expects to generate about 18 billion dollars in free cash flow in 2025. This provides ample coverage for dividends while maintaining investment in R&D and strategic acquisitions.
The company faces no major patent cliffs until the 2030s, giving long-term stability to ABBV dividends and reinforcing confidence similar to other companies with more than 50-year dividend growth streaks.
Shares trade around 16 times forward earnings, a discounted valuation for a pharmaceutical leader expecting high single-digit revenue growth through the decade.
Growth Engines in the Post-Humira Era
AbbVie has shifted from Humira dependence to a broader set of growth drivers. Skyrizi and Rinvoq continue expanding into new treatment areas, showing powerful double-digit growth and demonstrating post-Humira transition strength.
Botox and the aesthetics business deliver consistent high-margin revenue. Neuroscience and oncology add diversification, while only about 9 percent of revenue is exposed to loss of exclusivity this decade, reducing long-term dividend risk.
Although one institutional investor recently trimmed its position, the move appears isolated and has not shifted broader income-investor sentiment toward the stock.
Key Dividend Dates for Investors
AbbVie’s next ex-dividend date is set for 15 April 2026, with payment scheduled for 15 May. With shares trading near 222 dollars, the annualized 6.92 dollar payout provides a forward yield of roughly 3.1%.
The five-year dividend growth rate stands at about 6.6%. AbbVie’s Chowder number near 9.7 offers an appealing mix of yield and growth for DRIP-focused and long-term dividend strategies.
Is AbbVie Still Appealing for Dividend Investors?
For investors prioritizing durable, defensive income, AbbVie remains a leading choice in large-cap healthcare. Its immunology franchise continues to expand, and the company maintains a robust pipeline of nearly 90 clinical candidates, helping support future revenue growth.
Recent analysis on AbbVie’s operational resilience highlights continued growth despite headwinds, reinforcing confidence in sustained dividend performance.
With dependable cash flow, stable valuation and a well-covered payout, ABBV dividends continue to offer a compelling combination of yield, growth and long-term reliability for income-focused portfolios.
